El Impella otorga seguridad en la ATC del TCI no protegido de alto riesgo

Patients with CABG History and new N-ST ACS: Routine Invasive Strategy?

Multiple studies support the use of an early invasive approach in high risk patients with non-ST elevation acute coronary syndrome (NST ACS). This benefit of an invasive strategy over the expected management has been shown in randomized studies and meta-analysis. Patients with a history of cardiac artery bypass graft (CABG) represent approximately 10% of ACS<a href="https://solaci.org/en/2024/06/10/patients-with-cabg-history-and-new-n-st-acs-routine-invasive-strategy/" title="Read more" >...</a>

Pronóstico al año en lesiones ateroscleróticas vs las no ateroscleróticas en pacientes con MINOCA

Long Term Outcomes of Hyperemic Stenosis Resistance Index (HSR) in Patients with Stable Chronic Angina

The hyperemic stenosis resistance index (HSR) was introduced as a more complete hemodynamic severity indicator of a coronary lesion. HSR combines both pressure drop across a lesion and the flow through it, therefore overcoming the limitations of traditional indices such as fractional flow reserve (FFR) and coronary flow reserve (CFR). The aim of this multicenter<a href="https://solaci.org/en/2024/06/06/long-term-outcomes-of-hyperemic-stenosis-resistance-index-hsr-in-patients-with-stable-chronic-angina/" title="Read more" >...</a>

Resultados alentadores de los balones cubiertos de Biolimus para el tratamiento de vasos pequeños

BIONYX: Onyx vs. Orsiro At 5 Years

Onyx is a zotarolimus-eluting stent (ZES), designed with thin struts and a platinum core that enhances its radiological visibility. This can be beneficial in complex situations with limited visibility, such as in patients who are obese or present severe calcification, two particularly frequent characteristics in diabetic or elderly patients. The BIONYX study was a randomized<a href="https://solaci.org/en/2024/06/05/bionyx-onyx-vs-orsiro-at-5-years/" title="Read more" >...</a>

Relación entre calidad del vaso distal y resultados en tratamiento percutáneo de las oclusiones totales crónicas

CART Technique for Chronic Total Occlusions

The retrograde technique has significantly improved the success of percutaneous treatment of chronic total occlusions (CTO). After crossing a collateral channel, creating a connection between the anterograde and retrograde systems is key. The most common technique for this is reverse controlled antegrade and retrograde subintimal tracking (reverse CART). This technique involves inflating a balloon over<a href="https://solaci.org/en/2024/05/31/cart-technique-for-chronic-total-occlusions/" title="Read more" >...</a>

El TAVI presenta menos IAM post procedimiento que la cirugía de reemplazo valvular aórtico

Microvascular Resistant Reserve: Impact on STEMI Patients

Coronary Microvascular Dysfunction (CMD) is being increasingly considered a common consequence of STEMI. Its presence partly explains the persistence of angina symptoms in over 50% of patients after PCI, despite successful epicardial artery reperfusion. Also, CMD has been independently associated with worse left ventricular ejection fraction recovery, which leads to worse prognosis, including recurrent events,<a href="https://solaci.org/en/2024/05/29/microvascular-resistant-reserve-impact-on-stemi-patients/" title="Read more" >...</a>

Dietas bajas en carbohidratos y progresión de la calcificación coronaria

REPLICA-EPICA 18 Registry: Using IVL in Calcified Coronary Lesions

The presence of calcification in the coronary arteries (CAC) remains the main challenge in the percutaneous treatment of these lesions. Various studies have demonstrated the association of CAC with unfavorable long-term outcomes. Intravascular lithotripsy (IVL) has emerged as an effective tool for fracturing calcified plaques. Studies evaluating this strategy have shown high device success rates,<a href="https://solaci.org/en/2024/05/28/replica-epica-18-registry-using-ivl-in-calcified-coronary-lesions/" title="Read more" >...</a>

¿Es la litotricia coronaria tan efectiva como la aterectomía rotacional?

Is Intravascular Lithotripsy Equally Effective in All Coronary Calcification Patterns?

Coronary calcifications pose a complex challenge with a high incidence (25% of all angioplasties), thus implying difficult management and adverse long-term outcomes, such as an increased risk of events, especially the need for repeat revascularization. The main mechanisms of long-term failure include stent underexpansion and, in particular, minimal post-deployment stent area. Intravascular lithotripsy (IVL) has<a href="https://solaci.org/en/2024/05/28/is-intravascular-lithotripsy-equally-effective-in-all-coronary-calcification-patterns/" title="Read more" >...</a>

TAVI: Balón expandible o autoexpandible ¿Cuál es la respuesta?

Third Generation Balloon-Expandable and Self-Expanding Valves: TAVR Meta- Analysis

TAVR’s significant advance has driven the development of valve technology, which is currently in its third generation.  Even though outcomes have improved, randomized studies are yet to compared balloon-expandable (BEV) vs self-expanding (SEV) valves in randomized studies, and we only have information from different analysis with contradicting conclusions.  This was a meta-analysis of 16 studies<a href="https://solaci.org/en/2024/05/24/third-generation-balloon-expandable-and-self-expanding-valves-tavr-meta-analysis/" title="Read more" >...</a>

EuroPCR 2024 | 2 Year Outcomes of the New Sirolimus Eluting Bioadaptor vs Resolute Onyx Zotarolimus Elulting Stent

Stent related adverse events after the first year see a constant 2-3% annual increase, reaching 20% by year 5 and 50% by year 10. BIOADAPTADOR RCT outcomes at 12 months have shown the safety and efficacy of DynamX Bioadaptor, establishing new reference parameters in arterial viability restoration. The aim of this study was to report<a href="https://solaci.org/en/2024/05/17/europcr-2024-2-year-outcomes-of-the-new-sirolimus-eluting-bioadaptor-vs-resolute-onyx-zotarolimus-elulting-stent/" title="Read more" >...</a>

EuroPCR 2024 | NOTION-2: TAVI vs SAVR, Randomized Study on Low-Risk Young Patients with Severe Tricuspid Disease or Bicuspid Stenosis

Many of the studies comparing TAVR against SAVR in low risk patients included patients between 70-75 years, excluding those with tricuspid valves.  This study included low surgical risk patients with severe aortic stenosis and symptoms, 75 years or younger. Participants were randomized 1:1 to receiving TAVR or SAVR, stratified according to sex, need for new<a href="https://solaci.org/en/2024/05/17/europcr-2024-notion-2-tavi-vs-savr-randomized-study-on-low-risk-young-patients-with-severe-tricuspid-disease-or-bicuspid-stenosis/" title="Read more" >...</a>